A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)

Conditions

Lung

What is the purpose of this trial?

The study consists of a Phase1b lead-in portion to determine the MTD of OMP-59R5 in combination with EP for 6 cycles followed a Phase 2, multicenter, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
OncoMed Pharmaceuticals
Dates:
04/29/2014
Last Updated:
Study HIC#:
1311013077